IRIS Accounts Production v24.3.0.553 01654137 Board of Directors 1.11.22 31.10.23 31.10.23 true false true true false false true false Ordinary A shares 1.00000 Ordinary B shares 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh016541372022-10-31016541372023-10-31016541372022-11-012023-10-31016541372021-10-31016541372021-11-012022-10-31016541372022-10-3101654137ns15:EnglandWales2022-11-012023-10-3101654137ns14:PoundSterling2022-11-012023-10-3101654137ns10:Director12022-11-012023-10-3101654137ns10:PrivateLimitedCompanyLtd2022-11-012023-10-3101654137ns10:FRS1022022-11-012023-10-3101654137ns10:Audited2022-11-012023-10-3101654137ns10:LargeMedium-sizedCompaniesRegimeForDirectorsReport2022-11-012023-10-3101654137ns10:LargeMedium-sizedCompaniesRegimeForAccounts2022-11-012023-10-3101654137ns10:FullAccounts2022-11-012023-10-3101654137ns10:OrdinaryShareClass12022-11-012023-10-3101654137ns10:OrdinaryShareClass22022-11-012023-10-3101654137ns10:Director32022-11-012023-10-3101654137ns10:Director42022-11-012023-10-3101654137ns10:RegisteredOffice2022-11-012023-10-3101654137ns10:Director22022-11-012023-10-3101654137ns5:CurrentFinancialInstruments2023-10-3101654137ns5:CurrentFinancialInstruments2022-10-3101654137ns5:Non-currentFinancialInstruments2023-10-3101654137ns5:Non-currentFinancialInstruments2022-10-3101654137ns5:ShareCapital2023-10-3101654137ns5:ShareCapital2022-10-3101654137ns5:RetainedEarningsAccumulatedLosses2023-10-3101654137ns5:RetainedEarningsAccumulatedLosses2022-10-3101654137ns5:ShareCapital2021-10-3101654137ns5:RetainedEarningsAccumulatedLosses2021-10-3101654137ns5:RetainedEarningsAccumulatedLosses2021-11-012022-10-3101654137ns5:RetainedEarningsAccumulatedLosses2022-11-012023-10-3101654137ns15:UnitedKingdom2022-11-012023-10-3101654137ns15:UnitedKingdom2021-11-012022-10-3101654137ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2022-11-012023-10-3101654137ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2021-11-012022-10-3101654137ns5:PlantEquipmentOtherAssetsUnderOperatingLeases2022-11-012023-10-3101654137ns5:PlantEquipmentOtherAssetsUnderOperatingLeases2021-11-012022-10-3101654137ns5:OwnedAssets2022-11-012023-10-3101654137ns5:OwnedAssets2021-11-012022-10-3101654137ns5:HirePurchaseContracts2022-11-012023-10-3101654137ns5:HirePurchaseContracts2021-11-012022-10-3101654137ns5:ShortLeaseholdAssetsns5:LandBuildings2022-10-3101654137ns5:PlantMachinery2022-10-3101654137ns5:FurnitureFittings2022-10-3101654137ns5:MotorVehicles2022-10-3101654137ns5:ShortLeaseholdAssetsns5:LandBuildings2022-11-012023-10-3101654137ns5:PlantMachinery2022-11-012023-10-3101654137ns5:FurnitureFittings2022-11-012023-10-3101654137ns5:MotorVehicles2022-11-012023-10-3101654137ns5:ShortLeaseholdAssetsns5:LandBuildings2023-10-3101654137ns5:PlantMachinery2023-10-3101654137ns5:FurnitureFittings2023-10-3101654137ns5:MotorVehicles2023-10-3101654137ns5:ShortLeaseholdAssetsns5:LandBuildings2022-10-3101654137ns5:PlantMachinery2022-10-3101654137ns5:FurnitureFittings2022-10-3101654137ns5:MotorVehicles2022-10-3101654137ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-10-3101654137ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-10-3101654137ns5:HirePurchaseContractsns5:WithinOneYear2023-10-3101654137ns5:HirePurchaseContractsns5:WithinOneYear2022-10-3101654137ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2023-10-3101654137ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2022-10-3101654137ns5:HirePurchaseContracts2023-10-3101654137ns5:HirePurchaseContracts2022-10-3101654137ns5:HirePurchaseContractsns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-10-3101654137ns5:HirePurchaseContractsns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-10-3101654137ns5:WithinOneYear2023-10-3101654137ns5:WithinOneYear2022-10-3101654137ns5:BetweenOneFiveYears2023-10-3101654137ns5:BetweenOneFiveYears2022-10-3101654137ns5:MoreThanFiveYears2023-10-3101654137ns5:MoreThanFiveYears2022-10-3101654137ns5:AllPeriods2023-10-3101654137ns5:AllPeriods2022-10-3101654137ns5:DeferredTaxation2022-10-3101654137ns5:DeferredTaxation2022-11-012023-10-3101654137ns5:DeferredTaxation2023-10-3101654137ns10:OrdinaryShareClass12023-10-3101654137ns10:OrdinaryShareClass22023-10-3101654137ns5:RetainedEarningsAccumulatedLosses2022-10-31
REGISTERED NUMBER: 01654137 (England and Wales)











Surepharm Services Limited

Strategic Report, Report of the Directors and

Financial Statements

for the Year Ended 31 October 2023






Surepharm Services Limited (Registered number: 01654137)

Contents of the Financial Statements
for the Year Ended 31 October 2023










Page

Company Information 1

Strategic Report 2

Report of the Directors 3

Report of the Independent Auditors 5

Income Statement 9

Other Comprehensive Income 10

Balance Sheet 11

Statement of Changes in Equity 12

Cash Flow Statement 13

Notes to the Cash Flow Statement 14

Notes to the Financial Statements 15


Surepharm Services Limited

Company Information
for the Year Ended 31 October 2023







DIRECTORS: R Yarwood
R J Smith
J E Kirk





REGISTERED OFFICE: Unit 2b Bretby Business Park
Ashby Road East
Bretby
Burton On Trent
Staffordshire
DE15 0YZ





REGISTERED NUMBER: 01654137 (England and Wales)





AUDITORS: Haines Watts Tamworth Limited
Chartered Accountants and Statutory Auditors
Sterling House
97 Lichfield Street
Tamworth
Staffordshire
B79 7QF

Surepharm Services Limited (Registered number: 01654137)

Strategic Report
for the Year Ended 31 October 2023


The directors present their strategic report for the year ended 31 October 2023.

REVIEW OF BUSINESS
Fair review of the business

Sales decreased by approximately £2.4 million year-on-year due to a small number of customer rationalisation activities given changes in end-market demands. A favourable shift in the product mix resulted in gross margins increasing. Despite these challenging market-driven changes, the cash generated from operations was largely neutral.

Principal risks and uncertainties

The market outlook for the year to 31 October 2024 remains challenging but we expect to see revenue grow. Inflationary pressures on the cost base continue to be carefully managed.

The group is actively managing these issues and it will continue its strategy to broaden its customer offering, including with new dosage formats and expanded geographical reach across formulation and development, regulatory support analysis, and manufacture and packaging with the introduction of new products and customers being actively pursued on this basis. The Directors are confident that these initiatives are starting to offset the near-term challenges and therefore the outlook for the group remains positive in the medium-term.

ON BEHALF OF THE BOARD:





J E Kirk - Director


29 October 2024

Surepharm Services Limited (Registered number: 01654137)

Report of the Directors
for the Year Ended 31 October 2023


The directors present their report with the financial statements of the company for the year ended 31 October 2023.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of manufacturing of healthcare products.

DIVIDENDS
No dividends will be distributed for the year ended 31 October 2023.

DIRECTORS
R Yarwood has held office during the whole of the period from 1 November 2022 to the date of this report.

Other changes in directors holding office are as follows:

R J Smith and J E Kirk were appointed as directors after 31 October 2023 but prior to the date of this report.

J Layland ceased to be a director after 31 October 2023 but prior to the date of this report.

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Surepharm Services Limited (Registered number: 01654137)

Report of the Directors
for the Year Ended 31 October 2023


AUDITORS
The auditors, Haines Watts Tamworth Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





J E Kirk - Director


29 October 2024

Report of the Independent Auditors to the Members of
Surepharm Services Limited


Opinion
We have audited the financial statements of Surepharm Services Limited (the 'company') for the year ended 31 October 2023 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement and Notes to the Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).
_
In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31 October 2023 and of its loss for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion

Emphasis of matter
We draw attention to Note 2 of the financial statements which, in the light of the group's balance sheet position, outlines the directors' opinion around the continued adoption of the going concern basis for preparation of the company's financial statements.

Our opinion is not modified in respect of this matter.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Report of the Independent Auditors to the Members of
Surepharm Services Limited


Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
Surepharm Services Limited


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- results of our enquiries of management about their own identification and assessment of the risks and irregularities
- any matters we identified having obtained an understanding of the company policies and procedures relating to
- identifying, evaluating and complying with laws and regulations and whether they are aware of any instances of
non-compliance
- detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or
alleged fraud
- the internal controls set up to mitigate risks of fraud or non-compliance with laws and regulations
- the matters discussed among the audit engagement team regarding how and where fraud might occur in the
financial statements and any potential indicators of fraud.
- obtaining an understanding of the legal and regulatory framework that the company operates in, focusing on those
laws and regulations that had a direct effect on the financial statements, including UK Companies Act 2006,
pensions and tax legislation
- provisions of other laws and regulations that do not have a direct effect on the financial statements but
compliance with which may be fundamental to the company's ability to operation or to avoid material penalty.

As a result of performing the above, we did not identify any key audit matters related to the potential risk of fraud or non-compliance with laws and regulations.

Audit response to risks identified

Our procedures to respond to risks identified included the following:

- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with
provisions of relevant laws and regulations described as having a direct effect on the financial statements
- enquiring of management concerning actual and potential legal action and claims
carrying out analytical procedure to identify any unusual or unexpected relationships that may indicate risks of
material misstatement due to fraud
- reading minutes of meetings of those charged with governance -in addressing the risk of fraud through
management override of controls, testing the appropriateness of journal entries and other adjustments; assessing
whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating
the business rationale of any significant transactions that are unusual or outside the normal course of business.
- considering performance targets and their influence on efforts made by management to manage earnings

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of
Surepharm Services Limited


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Darren Barlow FCCA (Senior Statutory Auditor)
for and on behalf of Haines Watts Tamworth Limited
Chartered Accountants and Statutory Auditors
Sterling House
97 Lichfield Street
Tamworth
Staffordshire
B79 7QF

29 October 2024

Surepharm Services Limited (Registered number: 01654137)

Income Statement
for the Year Ended 31 October 2023

2023 2022
Notes £    £    £    £   

TURNOVER 3 11,925,430 14,305,198

Cost of sales 7,338,224 9,641,846
GROSS PROFIT 4,587,206 4,663,352

Distribution costs 202,509 182,180
Administrative expenses 5,721,678 5,362,461
5,924,187 5,544,641
OPERATING LOSS 5 (1,336,981 ) (881,289 )

Interest receivable and similar income 45,317 5,378
(1,291,664 ) (875,911 )

Interest payable and similar expenses 6 4,766 64,689
LOSS BEFORE TAXATION (1,296,430 ) (940,600 )

Tax on loss 7 (330,034 ) (179,174 )
LOSS FOR THE FINANCIAL YEAR (966,396 ) (761,426 )

Surepharm Services Limited (Registered number: 01654137)

Other Comprehensive Income
for the Year Ended 31 October 2023

2023 2022
Notes £    £   

LOSS FOR THE YEAR (966,396 ) (761,426 )


OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME FOR
THE YEAR

(966,396

)

(761,426

)

Surepharm Services Limited (Registered number: 01654137)

Balance Sheet
31 October 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 8 1,372,774 1,408,626

CURRENT ASSETS
Stocks 9 1,826,311 1,719,959
Debtors 10 6,899,564 6,849,516
Cash at bank and in hand 1,791,768 1,441,809
10,517,643 10,011,284
CREDITORS
Amounts falling due within one year 11 7,294,296 5,711,383
NET CURRENT ASSETS 3,223,347 4,299,901
TOTAL ASSETS LESS CURRENT
LIABILITIES

4,596,121

5,708,527

CREDITORS
Amounts falling due after more than one year 12 (90,062 ) -

PROVISIONS FOR LIABILITIES 15 - (236,072 )
NET ASSETS 4,506,059 5,472,455

CAPITAL AND RESERVES
Called up share capital 16 200 200
Retained earnings 17 4,505,859 5,472,255
SHAREHOLDERS' FUNDS 4,506,059 5,472,455

The financial statements were approved by the Board of Directors and authorised for issue on 29 October 2024 and were signed on its behalf by:





J E Kirk - Director


Surepharm Services Limited (Registered number: 01654137)

Statement of Changes in Equity
for the Year Ended 31 October 2023

Called up
share Retained Total
capital earnings equity
£    £    £   
Balance at 1 November 2021 200 6,233,681 6,233,881

Changes in equity
Total comprehensive income - (761,426 ) (761,426 )
Balance at 31 October 2022 200 5,472,255 5,472,455

Changes in equity
Total comprehensive income - (966,396 ) (966,396 )
Balance at 31 October 2023 200 4,505,859 4,506,059

Surepharm Services Limited (Registered number: 01654137)

Cash Flow Statement
for the Year Ended 31 October 2023

2023 2022
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 (133,344 ) 2,041,598
Interest paid - (46,107 )
Interest element of hire purchase payments
paid

(4,766

)

(18,582

)
Tax paid 138,703 (299,704 )
Net cash from operating activities 593 1,677,205

Cash flows from investing activities
Purchase of tangible fixed assets (239,470 ) (201,366 )
Interest received 45,317 5,378
Net cash from investing activities (194,153 ) (195,988 )

Cash flows from financing activities
Loan repayments in year - (2,861,549 )
Intercompany balance movements 566,448 2,941,467
Capital repayments in year (22,929 ) (290,117 )
Net cash from financing activities 543,519 (210,199 )

Increase in cash and cash equivalents 349,959 1,271,018
Cash and cash equivalents at beginning of
year

2

1,441,809

170,791

Cash and cash equivalents at end of year 2 1,791,768 1,441,809

Surepharm Services Limited (Registered number: 01654137)

Notes to the Cash Flow Statement
for the Year Ended 31 October 2023


1. RECONCILIATION OF LOSS BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

2023 2022
£    £   
Loss before taxation (1,296,430 ) (940,600 )
Depreciation charges 433,044 517,728
Finance costs 4,766 64,689
Finance income (45,317 ) (5,378 )
(903,937 ) (363,561 )
(Increase)/decrease in stocks (106,352 ) 121,809
(Increase)/decrease in trade and other debtors (63,624 ) 1,603,786
Increase in trade and other creditors 940,569 679,564
Cash generated from operations (133,344 ) 2,041,598

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 October 2023
31.10.23 1.11.22
£    £   
Cash and cash equivalents 1,791,768 1,441,809
Year ended 31 October 2022
31.10.22 1.11.21
£    £   
Cash and cash equivalents 1,441,809 170,791


3. ANALYSIS OF CHANGES IN NET FUNDS

Other
non-cash
At 1.11.22 Cash flow changes At 31.10.23
£    £    £    £   
Net cash
Cash at bank
and in hand 1,441,809 349,959 1,791,768
1,441,809 349,959 1,791,768
Debt
Finance leases - 22,929 - (134,793 )
- 22,929 - (134,793 )
Total 1,441,809 372,888 - 1,656,975

Surepharm Services Limited (Registered number: 01654137)

Notes to the Financial Statements
for the Year Ended 31 October 2023


1. STATUTORY INFORMATION

Surepharm Services Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern
The Company and wider group had a challenging year reporting pre tax losses and a deterioration in the shareholder's funds position, due to accrued shareholder loan note interest which is not repayable until sale of the group. The group is actively managing these issues and has several initiatives in place to improve performance. The Directors are confident that these initiatives are starting to offset the near-term challenges and therefore the outlook for the group remains positive in the medium-term.

The group refinanced during the summer of 2024 and has also obtained additional loan and equity capital from the shareholders, including in October 2024. The Directors believe this capital will provide sufficient headroom for the group to continue to trade as a going concern at least for the next 12 months. The recent capital injection also demonstrates the ongoing support of the shareholders, providing further confidence in the group's ability to trade as a going concern.

The directors therefore continue to adopt the going concern basis in preparing the financial statements which assumes the group will continue to operate for the foreseeable future. The financial statements do not include any adjustments that would result from this basis of preparation being inappropriate. Should the going concern basis cease to be appropriate, adjustments might be required to write down assets to recoverable amounts, reclassify fixed assets and long-term liabilities as current and recognise additional liabilities.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Surepharm Services Limited (Registered number: 01654137)

Notes to the Financial Statements - continued
for the Year Ended 31 October 2023


2. ACCOUNTING POLICIES - continued

Significant judgements and estimates
In the application of the company's accounting policies, the directors are required to make judgement, estimates and assumptions about carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of revision and future periods where the revision affects both current and future periods.

In preparing these financial statements the directors have made judgements including:

Useful economic lives of tangible fixed assets

The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are assessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets.

Leasing obligations

Determine whether leases entered into by the company either as a lessor or a lessee are operating or finance leases. These decisions depend on an assessment of whether the risks and rewards of ownership have been transferred from the lessor to the lessee on a lease by lease basis based on an evaluation of the terms and conditions of the arrangements, and accordingly whether the lease requires an asset and liability to be recognised in the statement of financial position.

Provisions

A provision is recognised when the company has a present legal or constructive obligation as a result of a past event for which it is probable that an outflow of resources will be required to settle the obligation and the amount can be reliably estimated. If the effect is material, provisions are determined by discounting the expected future cash flow at a rate that reflects the time value of money and the risks specific to the liability.

Whether a present obligation is probable or not requires judgement. The nature and type of risks for these provisions differ and management's judgement is applied regarding the nature and extent of obligations in deciding if an outflow of resources is probable or not.

Sales ledger bad debt provisions

Management review debts on a case by case basis to highlight deviation from terms and therefore possible provision requirement.

Stock provisions

Through experience over time, the management have formulated a standard policy of provisioning based on stock movement. This is monitored on an ongoing basis and judgement used on a line by line basis should trends change significantly.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Surepharm Services Limited (Registered number: 01654137)

Notes to the Financial Statements - continued
for the Year Ended 31 October 2023


2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life:

Short leaseholdover term of the lease
Plant and machinery15% straight line
Punches and dies (plant and machinery)33% straight line
Fixtures and fittings15% reducing balance
Computer equipment25% straight line
Motor vehicle33% straight line

Stocks
Stocks and work in progress are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Cost is calculated using the first-in, first-out method and includes all purchase, transport, and handling costs in bringing stocks to their present location and condition.

Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are
measured initially at fair value, net of transaction costs, and are measured subsequently at
amortised cost using the effective interest method, less any impairment.

Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank
loans, are measured initially at fair value, net of transaction costs, and are measured subsequently
at amortised cost using the effective interest method.

Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without
penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that
mature in no more than three months from the date of acquisition and that are readily convertible to
known amounts of cash with insignificant risk of change in value.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Surepharm Services Limited (Registered number: 01654137)

Notes to the Financial Statements - continued
for the Year Ended 31 October 2023


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. TURNOVER

The turnover and loss before taxation are attributable to the one principal activity of the company.

An analysis of turnover by geographical market is given below:

2023 2022
£    £   
United Kingdom 9,629,722 11,849,197
Rest of World 2,295,708 2,456,001
11,925,430 14,305,198

4. EMPLOYEES AND DIRECTORS
2023 2022
£    £   
Wages and salaries 3,980,836 4,170,427
Social security costs 379,502 392,874
Other pension costs 164,777 145,896
4,525,115 4,709,197

The average number of employees during the year was as follows:
2023 2022

Production staff 100 116
Administrative staff 18 20
118 136

Surepharm Services Limited (Registered number: 01654137)

Notes to the Financial Statements - continued
for the Year Ended 31 October 2023


4. EMPLOYEES AND DIRECTORS - continued

2023 2022
£    £   
Directors' remuneration - 33,798

5. OPERATING LOSS

The operating loss is stated after charging:

2023 2022
£    £   
Hire of plant and machinery 43,212 56,837
Depreciation - owned assets 433,044 517,727
Auditors' remuneration 16,620 20,000
Foreign exchange differences 27,753 32,487

6. INTEREST PAYABLE AND SIMILAR EXPENSES
2023 2022
£    £   
Bank interest - 14,794
Bank loan interest - 31,313
Hire purchase 4,766 18,582
4,766 64,689

7. TAXATION

Analysis of the tax credit
The tax credit on the loss for the year was as follows:
2023 2022
£    £   
Current tax:
Prior year tax adjustment - (138,703 )

Deferred tax (330,034 ) (40,471 )
Tax on loss (330,034 ) (179,174 )

Surepharm Services Limited (Registered number: 01654137)

Notes to the Financial Statements - continued
for the Year Ended 31 October 2023


7. TAXATION - continued

Reconciliation of total tax credit included in profit and loss
The tax assessed for the year is lower than the standard rate of corporation tax in the UK. The difference is explained below:

2023 2022
£    £   
Loss before tax (1,296,430 ) (940,600 )
Loss multiplied by the standard rate of corporation tax in the UK of 25%
(2022 - 19%)

(324,108

)

(178,714

)

Effects of:
Capital allowances in excess of depreciation (22,496 ) -
Depreciation in excess of capital allowances - 40,011
Group relief 1,896 -
Deferred tax movement 14,674 (40,471 )
Total tax credit (330,034 ) (179,174 )

8. TANGIBLE FIXED ASSETS
Fixtures
Short Plant and and Motor
leasehold machinery fittings vehicles Totals
£    £    £    £    £   
COST
At 1 November 2022 181,643 7,642,547 2,618,133 8,600 10,450,923
Additions - 293,249 103,943 - 397,192
At 31 October 2023 181,643 7,935,796 2,722,076 8,600 10,848,115
DEPRECIATION
At 1 November 2022 181,640 6,636,371 2,215,686 8,600 9,042,297
Charge for year 3 303,513 129,528 - 433,044
At 31 October 2023 181,643 6,939,884 2,345,214 8,600 9,475,341
NET BOOK VALUE
At 31 October 2023 - 995,912 376,862 - 1,372,774
At 31 October 2022 3 1,006,176 402,447 - 1,408,626

9. STOCKS
2023 2022
£    £   
Stocks 1,498,048 1,489,988
Work-in-progress 328,263 229,971
1,826,311 1,719,959

Surepharm Services Limited (Registered number: 01654137)

Notes to the Financial Statements - continued
for the Year Ended 31 October 2023


10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 2,703,666 2,820,690
Amounts owed by group undertakings 3,718,660 3,687,495
Other debtors 20,177 -
Tax - 138,703
Deferred tax asset 93,962 -
Prepayments 363,099 202,628
6,899,564 6,849,516

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Hire purchase contracts (see note 13) 44,731 -
Trade creditors 1,850,018 1,441,841
Amounts owed to group undertakings 3,720,782 3,123,169
Social security and other taxes 99,384 93,086
VAT 387,011 284,426
Other creditors 740,681 256,003
Wages control 32,626 22,491
Accruals and deferred income 419,063 490,367
7,294,296 5,711,383

12. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2023 2022
£    £   
Hire purchase contracts (see note 13) 90,062 -

Surepharm Services Limited (Registered number: 01654137)

Notes to the Financial Statements - continued
for the Year Ended 31 October 2023


13. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Hire purchase contracts
2023 2022
£    £   
Gross obligations repayable:
Within one year 51,205 -
Between one and five years 103,456 -
154,661 -

Finance charges repayable:
Within one year 6,474 -
Between one and five years 13,394 -
19,868 -

Net obligations repayable:
Within one year 44,731 -
Between one and five years 90,062 -
134,793 -

Non-cancellable operating leases
2023 2022
£    £   
Within one year 500,395 500,395
Between one and five years 1,959,417 2,001,580
In more than five years - 458,232
2,459,812 2,960,207

14. SECURED DEBTS

The following secured debts are included within creditors:

2023 2022
£    £   
Hire purchase contracts 134,793 -

Bank loans and overdrafts are secured by way of fixed and floating charges over the undertaking and its assets, both present and future.

Hire purchase and finance lease obligations are secured by way of a charge over the assets to which they relate.

15. PROVISIONS FOR LIABILITIES
2022
£   
Deferred tax 236,072

Surepharm Services Limited (Registered number: 01654137)

Notes to the Financial Statements - continued
for the Year Ended 31 October 2023


15. PROVISIONS FOR LIABILITIES - continued

Deferred
tax
£   
Balance at 1 November 2022 236,072
Utilised during year (330,034 )
Balance at 31 October 2023 (93,962 )

16. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
100 Ordinary A shares £1 100 100
100 Ordinary B shares £1 100 100
200 200

17. RESERVES
Retained
earnings
£   

At 1 November 2022 5,472,255
Deficit for the year (966,396 )
At 31 October 2023 4,505,859

18. ULTIMATE PARENT COMPANY

The parent undertaking is Centaur Healthcare Limited, a company incorporated in England, whose Registered Office is Bretby Business Park, Bretby, Burton upon Trent, Staffordshire, DE15 0YZ.

The ultimate parent is Surepharm Topco Limited, registered at the same address. Consolidated financial statements for the group can be obtained from Companies House, Crown Way, Cardiff, CF14 3UZ.

19. CONTINGENT LIABILITIES

The company is subject to group financing arrangements over which there are composite guarantees and debentures. Amounts secured on group assets relate to long term loans being repaid by instalment which totalled £13,102,932 (2022 - £14,881,097) at the balance sheet date. The directors feel there is no uncertainty regarding reimbursement or the timing of cashflows in this respect.

20. CAPITAL COMMITMENTS
2023 2022
£    £   
Contracted but not provided for in the
financial statements 744,439 -